More recently it has been shown that inhibiting CXCR4 with plerixafor®, a small molecule antagonist to the receptor, reduces fibrosis in breast cancers that have metastasized to the lungs and liver, increases T-lymphocyte infiltration, and more than doubles the sensitivity of breast cancer cells to immunotherapy [220]. The gene discussed is CXCR4; the disease is breast carcinoma.